SWOG S1712

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

For more information about this clinical trial, click here

Schema & Eligibility SWOG S1712

Available at:

CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Delbert Day Cancer Institute at PCRMC, Rolla, MO
Freeman Health System, Joplin, MO
Good Samaritan Regional Health Center, Mt. Vernon, IL
Mercy Hospital, St. Louis, MO
Mercy South, St. Louis, MO
Mercy Hospital, Oklahoma City, OK
Mercy Hospital, Joplin, MO
Mercy Clinic Cancer & Hematology, Rolla, MO
Mosaic Life Care, St. Joseph, MO

Ask your physician about participating in this clinical trial or call us.